Carbidopa/Levodopa Shortage Update: What Patients Need to Know in 2026

The Carbidopa/Levodopa Shortage: Where Things Stand in 2026

If you depend on Carbidopa/Levodopa for your Parkinson's disease, you've probably experienced the frustration firsthand: your pharmacy is out, they don't know when they'll get more, and nobody seems to have clear answers.

In this article, we'll give you the most current picture of the Carbidopa/Levodopa supply situation in 2026, explain what's driving the shortage, break down the costs, and tell you exactly what you can do to keep your treatment on track.

Is Carbidopa/Levodopa Still in Shortage?

The answer depends on which formulation you need:

• Immediate-release (IR) tablets — Generally available from multiple generic manufacturers. Spot shortages still occur at individual pharmacies, but overall supply is relatively stable.
• Extended-release (ER/CR) tablets — This is where the biggest problems are. Accord Healthcare discontinued the 25/100 mg ER tablet entirely. Only a few manufacturers still make the ER formulation, and supply has been inconsistent.
• Orally disintegrating tablets (ODT) — Sun Pharma discontinued the 25/250 mg ODT, creating shortages for patients who need this formulation — particularly those with swallowing difficulties.
• Brand-name products — Rytary, Crexont, and Duopa are not in shortage per se, but they're expensive and not always stocked at retail pharmacies.

The American Society of Health-System Pharmacists (ASHP) continues to track the shortage of both ER tablets and ODT formulations on their drug shortage list.

Why Is Carbidopa/Levodopa Hard to Find?

Several factors are converging to create this problem:

Manufacturer Exits

When a generic medication is inexpensive, the profit margins are razor-thin. This has led some manufacturers to simply stop making certain Carbidopa/Levodopa products. Fewer manufacturers means less supply and less resilience when one company has a production issue.

Growing Demand

Nearly one million Americans live with Parkinson's disease, and that number is rising as the population ages. More patients are being diagnosed every year, which increases demand for Carbidopa/Levodopa — the first-line treatment for most people with PD.

Supply Chain Complexity

Pharmaceutical supply chains span the globe. Active pharmaceutical ingredients (APIs) are often manufactured overseas, and disruptions at any point — from raw material sourcing to shipping to final manufacturing — can affect availability in the U.S.

The "8 Tablet Limit" Problem

An ongoing issue specific to Carbidopa/Levodopa is the so-called "eight Sinemet limit." Some pharmacies and insurance companies cite language from the original FDA approval of Sinemet to deny prescriptions for patients who need more than eight tablets per day. This doesn't affect supply directly, but it adds another barrier for patients trying to access adequate treatment.

For a deeper dive into why this medication is hard to find, see our article on why Carbidopa/Levodopa is so hard to find in 2026.

What Does Carbidopa/Levodopa Cost in 2026?

One silver lining: generic Carbidopa/Levodopa remains one of the more affordable Parkinson's medications:

• Generic IR tablets (25/100 mg, 30 tablets): $8 to $17 retail; as low as $9 with a GoodRx coupon
• Generic IR tablets (25/250 mg, 30 tablets): $10 to $20 retail
• Generic ER tablets (50/200 mg, 100 tablets): $30 to $40 retail
• Rytary (brand, 100 capsules): $322 to $403 retail
• Crexont (brand): Pricing varies; check with your pharmacy or insurance

With insurance, most patients pay $0 to $15 for generic Carbidopa/Levodopa, as it's typically classified as a Tier 1 preferred generic.

For detailed savings strategies, see our guide on how to save money on Carbidopa/Levodopa in 2026.

Are There New Options in 2026?

Yes. The Parkinson's treatment landscape continues to evolve:

• Crexont — Approved in 2024, this is the newest extended-release Carbidopa/Levodopa capsule. It uses a multi-bead technology for both immediate and sustained release, allowing for twice-daily dosing in many patients. It may be an option if you're having trouble finding ER tablets.
• Stalevo (Carbidopa/Levodopa/Entacapone) — While not new, this combination product may be available when standard Carbidopa/Levodopa is not. It includes Entacapone, which extends the duration of each dose.

Your neurologist can help you decide if these options make sense for your treatment plan. For other options, read about alternatives to Carbidopa/Levodopa.

How to Find Carbidopa/Levodopa in Stock Right Now

Here's your action plan:

1. Search on Medfinder: Use Medfinder to find pharmacies near you with Carbidopa/Levodopa in stock. It's the fastest way to locate your medication.
2. Try independent pharmacies: They often have different supply sources than the big chains.
3. Ask your pharmacist to order it: Even if it's not on the shelf, your pharmacist may be able to get it from their distributor within 1-2 days.
4. Consider mail-order: Services like Amazon Pharmacy may have better stock for 90-day supplies.
5. Talk to your doctor: If your specific formulation is unavailable, your doctor can prescribe an alternative strength or form.

For a complete walkthrough, read our guide on how to find Carbidopa/Levodopa in stock near you.

Final Thoughts

The Carbidopa/Levodopa shortage in 2026 is real but manageable. Immediate-release tablets are generally available if you know where to look, though extended-release and ODT formulations remain harder to find. Prices for the generic version are still affordable, and new formulations like Crexont are expanding options for patients.

The most important thing you can do is plan ahead. Don't wait until your last pill to start looking. Use Medfinder, work with your pharmacist, and stay in communication with your doctor. And remember — never stop Carbidopa/Levodopa abruptly.

Learn more about this medication's side effects and drug interactions.